https://www.databridgemarketresearch.com/reports/north-america-bacteriophages-therapy-market

https://www.databridgemarketresearch.com/reports/middle-east-and-africa-bacteriophages-therapy-market

https://www.databridgemarketresearch.com/reports/asia-pacific-bacteriophages-therapy-market

https://www.databridgemarketresearch.com/reports/europe-bacteriophages-therapy-market

https://www.databridgemarketresearch.com/reports/global-bacteriophages-therapy-market

Bacteriophage therapy market Growth Analysis and Forecast by 2035 With the ever-increasing burden of antimicrobial resistance, the focus of the research community has shifted towards the development of alternatives for the treatment of infectious diseases. One of such alternatives is bacteriophage therapeutics. The innovators suggests that the success of these therapies lies in the effectiveness of phages to target the desired bacterial strains. The financial opportunity within the bacteriophage therapeutics market has been analyzed across the following segments:  Type of Therapeutic Area  Infectious Diseases  Oncological Disorders  Other Disorders  Distribution by Route of Administration  Oral Route  Rectal Route  Intravesical Route  Topical Route  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa The “Bacteriophage Therapies Market, 2022-2035” report features the following companies, which we identified to be key players in this domain:  Adaptive Phage Therapeutics  ContaFect  Eliava BioPreparations  Micreos  NPO Microgen  Phagelux  Pherecydes Pharma Table of Content 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. BACTERIO-PHAGE THERAPY: MARKET LANDSCAPE 5. BACTERIO-PHAGE THERAPEUTICS: DEVELOPER LANDSCAPE 6. COMPANY AND DRUG PROFILES 7. CLINICAL TRIAL ANALYSIS 8. PATENT ANALYSIS 9. PUBLICATION BENCHMARKING ANALYSIS 10. ACADEMIC GRANTS ANALYSIS 11. FUNDING AND INVESTMENT ANALYSIS 12. PARTNERSHIPS AND COLLABORATIONS 13. START-UP HEALTH INDEXING 14. MARKET FORECAST AND OPPORTUNITY ANALYSIS 15. CONCLUSION 16. EXECUTIVE INSIGHTS 17. APPENDIX I: TABULATED DATA 18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html Learn from experts: do you know about these emerging industry trends? Rare Kidney Disorders: Future Miracle Drugs Smart pharmaceutical and healthcare labels: Lets trace medicines from its origin Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Learn more about Roots Analysis consulting services: Roots Analysis Consulting - the preferred research partner for global firms Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #bacteriophagetherapeutics #bacteriophagetherapies #bacteriophagemarket #Marketresearch #MarketInsights

Bacteriophage therapy market Professional Survey Report by 2035 With the ever-increasing burden of antimicrobial resistance, the focus of the research community has shifted towards the development of alternatives for the treatment of infectious diseases. One of such alternatives is bacteriophage therapeutics. The innovators suggests that the success of these therapies lies in the effectiveness of phages to target the desired bacterial strains. The financial opportunity within the bacteriophage therapeutics market has been analyzed across the following segments:  Type of Therapeutic Area  Infectious Diseases  Oncological Disorders  Other Disorders  Distribution by Route of Administration  Oral Route  Rectal Route  Intravesical Route  Topical Route  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa The “Bacteriophage Therapy Market, 2022-2035” report features the following companies, which we identified to be key players in this domain:  Adaptive Phage Therapeutics  ContaFect  Eliava BioPreparations  Micreos  NPO Microgen  Phagelux  Pherecydes Pharma Table of Content 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. BACTERIO-PHAGE THERAPY: MARKET LANDSCAPE 5. BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE 6. COMPANY AND DRUG PROFILES 7. CLINICAL TRIAL ANALYSIS 8. PATENT ANALYSIS 9. PUBLICATION BENCHMARKING ANALYSIS 10. ACADEMIC GRANTS ANALYSIS 11. FUNDING AND INVESTMENT ANALYSIS 12. PARTNERSHIPS AND COLLABORATIONS 13. START-UP HEALTH INDEXING 14. MARKET FORECAST AND OPPORTUNITY ANALYSIS 15. CONCLUSION 16. EXECUTIVE INSIGHTS 17. APPENDIX I: TABULATED DATA 18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html You may also be interested in the following titles: Cannabis Testing Market Key Trends in Non-Viral Transfection Market CAR-T Cell Therapy Market Roots Analysis Consulting - the preferred research partner for global firms About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #bacteriophagetherapy #bacteriophagetherapeutics #phagetherapy #MarketResearch #MarketInsights

Bacteriophage therapeutics market Research Report by 2022, Forecast till 2035 The ‘Bacteriophage Therapeutics Market, 2022-2035’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics, over the coming few years Key Inclusions  A summary of the key insights from the bacteriophage therapeutics market. It offers a high-level view on the current state of the market and its likely evolution in the mid to long term.  A general overview of the historical evolution of bacteriophages and their biology. It also includes a detailed discussion on applications of bacteriophage therapy. The chapter concludes with a discussion on the various advantages and limitations associated with the bacteriophage therapy.  A detailed overview of the overall market landscape of bacteriophage therapeutics, including information on their current status of development (marketed, clinical, preclinical and discovery), key therapeutic areas (infectious diseases, oncological disorders, and other disorders), type of bacterial strain (Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Salmonella, Streptococcus, Acinetobacter baumannii and others), target disease indication (lung infection, bone infection, urinary tract infection, gastrointestinal infection, bacterial infection, blood infection, other disorders, and multiple infections), type of therapy (monotherapy, combination therapy, and both), route of administration (oral route, topical route, rectal route and intravenous route), and information on bacteriophage related technologies.  An overview of the current status of the market with respect to the players engaged in the manufacturing of bacteriophage therapeutics, featuring information on the year of establishment, company size, location of headquarters, and leading developers.  Elaborate profiles of the prominent players engaged in the development of bacteriophage therapeutics (shortlisted based on the number of drugs progressed to advanced phases of development). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, and a section on recent developments and an informed future outlook.  An in-depth analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, trial phase, enrolled patient population, study design, type of sponsor / collaborator, most active players (in terms of number of registered trials), registered trials, and geographical region (by number of registered trials and number of enrolled patient population).  An in-depth analysis of the various patents that have been filed / granted related to bacteriophage therapeutics. It includes information on key parameters, such as type of patent (granted patents, patent applications and others), publication year, application year, number of granted patents and patent applications, geographical distribution, Cooperative Patent Classification (CPC) symbols, and type of applicant. It also highlights the leading industry and non-industry players and individual assignees (in terms of number of patents filed / granted).  An in-depth analysis of various publications for bacteriophage therapeutics, based on several relevant parameters, such as year of publication, type of article, popular keywords, most popular publishers (in terms of number of publications), key journals (in terms of number of articles published and journal impact factor). It also highlights benchmarking of the publications to develop more insightful opinions on the recent trends related to research and development in this area.  A detailed study of the various grants that have been awarded to research institutes engaged in projects related to bacteriophage therapeutics, since 2017, highlighting various important parameters, such as year of award, amount awarded, funding institute, support period, grant type, purpose of grant, focus area, type of recipient organization, and leading recipient organizations.  An in-depth analysis of the investments made, including grants, venture capital financing, initial public offering, secondary offering, private placement, equity and debt funding, at various stages of development, in companies that are focused on developing bacteriophage therapeutics.  A detailed study of the recent collaborations and partnership established in this domain since 2017, including the details of deals that were / are focused on the development of bacteriophage therapeutics, which were analyzed based on several parameters such as year of partnership, type of partnership (research and development agreement, product development agreement, licensing agreement, merger / acquisition, commercialization agreement, manufacturing agreement, clinical trial agreement, supply agreement, distribution agreement and other agreement), therapeutic area (infectious diseases, hepatological disorders, chronic inflammatory disorders, skin disorders and women’s health), application areas (human health, animal health, diagnostic test, aquaculture, food safety, food safety and environment protection and livestock farming), and regional distribution of partnerships.  An analysis of the various start-ups engaged in the development of bacteriophage therapeutics, based on relevant parameters, such as pipeline strength, pipeline maturity, indication diversity, number of patents, financial support and partnership activity The financial opportunity within the bacteriophage therapy market has been analyzed across the following segments:  Type of Therapeutic Area  Infectious Diseases  Oncological Disorders  Other Disorders  Distribution by Route of Administration  Oral Route  Rectal Route  Intravesical Route  Topical Route  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa The report features inputs from eminent industry stakeholders, according to whom upcoming generations of bacteriophage therapeutics are likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts:  Antoine Culot (Chief Executive Officer, Rime Bioinformatics)  Mathieu Medina (Project Leader, Hospices Civils De Lyon)  Iddo Weiner (Senior Director, Head of Data-Science, BiomX)  Mohammadreza Azizkhani (Independent Consultant) Key Questions Answered  Which bacteriophage therapeutics candidates are currently under clinical stage of development pipeline?  Who are the leading players engaged in the development of bacteriophage therapeutics?  Which geographies are the most active in conducting clinical trials related to bacteriophage therapeutics?  What is the focus of various publications related to bacteriophage therapeutics?  Which partnership models are commonly adopted by industry and non-industry stakeholders?  What are the investment trends in the industry?  What are the different initiatives undertaken by start-ups for the development of bacteriophage therapeutics in the recent past?  How is the current and future market opportunity likely to be distributed across key market segments? For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html You may also be interested in the following titles: Lab Automation Market Cannabis Testing Market You may also like to learn what our experts are sharing in Roots educational series: Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders 4D Bioprinting Market: Key Trends About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #Bacteriophagetherapeuticsmarket #Bacteriophagetherapeuticsmarketsize #bacteriophage #phage #bacteriophagetherapy

The bacteriophage therapeutics market is anticipated to grow at a CAGR of 10%, till 2035, claims Roots Analysis Given the low toxicity, specific targeting and ability to offer higher biosafety, the bacteriophage therapeutics are actively being evaluated for the treatment of various infectious diseases London Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings. With the ever-increasing burden of antimicrobial resistance, the focus of the research community has shifted towards the development of alternatives for the treatment of infectious diseases. One of such alternatives is bacteriophage therapeutics. The innovators suggests that the success of these therapies lies in the effectiveness of phages to target the desired bacterial strains. With the growing need for therapies targeting AMR infections, bacteriophage therapy is now gaining more traction. Key Market Insights Close to 15 bacteriophage therapeutics are commercialized, while more than 90 are currently at different stages of development Close to 50% of the pipeline candidates are under clinical evaluation; majority (91%) of these candidates are being developed for the treatment of infectious diseases, targeting wide range of bacterial strains. 40+ industry stakeholders claim to have the required capability to manufacture bacteriophage therapeutics The bacteriophage therapy market is currently dominated by the presence of various small players (48%); of these 55% of the players are located in North America, followed by Europe (35%). More than 2,200 articles focused on bacteriophage therapeutics have been published, since 2018 Around 40% of these were published in the last two years, indicating the extensive research activity being carried out in this domain. Close to USD 1,200 million has been invested by both private and public investors, since 2017 Of the total amount invested, over USD 330 million was raised through venture capital funding, representing close to 30% of the overall funding activity in this domain. Further, close to 40% of the instances were, wherein players were collectively awarded more than USD 300 million. Partnership activity within this domain has grown significantly between the time period, 2017-2021 Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that, majority of the deals were related to the research and development (20%), followed by agreements signed for product development (15%). More than 3,500 patients have been enrolled in over 40 clinical trials, worldwide Clinical research activity, in terms of number of trials registered, is reported to has significantly increased in the past few years. Of the total number of trials, close to 35% have already been completed, while 41% are active and still recruiting patients. Europe are anticipated to capture larger share (~95%) of the market by 2035 Currently, in bacteriophage therapeutics market, gastrointestinal infections capture the highest share (~50%) and this trend is unlikely to change in the foreseen future. Further, more than 55% share of the market is captured by oral bacteriophage therapeutics. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market/request-sample.html Key Questions Answered  Which bacteriophage therapeutics candidates are currently under clinical stage of development pipeline?  Who are the leading players engaged in the development of bacteriophage therapeutics?  Which geographies are the most active in conducting clinical trials related to bacteriophage therapeutics?  What is the focus of various publications related to bacteriophage therapeutics?  Which partnership models are commonly adopted by industry and non-industry stakeholders?  What are the investment trends in the industry?  What are the different initiatives undertaken by start-ups for the development of bacteriophage therapeutics in the recent past?  How is the current and future market opportunity likely to be distributed across key market segments? The financial opportunity within the bacteriophage therapeutics market has been analyzed across the following segments:  Type of Therapeutic Area  Gastrointestinal Infections  Bacterial Dysentery  Multiple Infections  Other Infections  Distribution by Route of Administration  Oral Route  Rectal Route  Intravesical Route  Topical Route  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa The report features inputs from eminent industry stakeholders, according to whom upcoming generations of bacteriophage therapeutics are likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts:  Antoine Culot (Chief Executive Officer, Rime Bioinformatics)  Mathieu Medina (Project Leader, Hospices Civils De Lyon)  Iddo Weiner (Senior Director, Head of Data-Science, BiomX)  Mohammadreza Azizkhani (Independent Consultant) The research also includes detailed profiles of key players (listed below), featuring an overview of the company, its financial information (if available), detailed information on the advanced stage pipeline candidates and an informed future outlook.  Adaptive Phage Therapeutics  ContaFect  Eliava BioPreparations  Micreos  NPO Microgen  Phagelux  Pherecydes Pharma For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html You may also be interested in the following titles: 1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035 2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com